Naureen Quibria
Stock Analyst at Capital One
(n/a)
# 4,650
Out of 5,055 analysts
8
Total ratings
11.11%
Success rate
-44.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $1.28 | +1,853.13% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $1.85 | +440.54% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $2.58 | +210.08% | 1 | Mar 11, 2024 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $35.99 | +133.40% | 1 | Aug 16, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $8.80 | +354.55% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $7.86 | +39.95% | 1 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $2.17 | +867.74% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | $900 | $6.27 | +14,254.07% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $1.28
Upside: +1,853.13%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $1.85
Upside: +440.54%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $2.58
Upside: +210.08%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $35.99
Upside: +133.40%
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $8.80
Upside: +354.55%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $7.86
Upside: +39.95%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $2.17
Upside: +867.74%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: $900
Current: $6.27
Upside: +14,254.07%